Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1999-1-5
|
pubmed:abstractText |
As a potent promoter of muscle growth, clenbuterol has been proposed as a treatment for muscle wasting diseases. Thus, the effects of clenbuterol on dystrophic skeletal muscle was examined. Male dystrophic (dy/dy) mice aged 4-5 weeks were treated with clenbuterol for 3 weeks, and the isometric contractile, fatigue and histochemical properties of the slow-twitch soleus and fast-twitch plantaris muscles measured. Muscles of dystrophic animals produced lower forces, contracted more slowly and exhibited greater fatigue resistance than age-matched normal animals. Dystrophic soleus muscles also had higher proportions of type I fibres than normal mice. Clenbuterol significantly reduced the natural death rate of dystrophic mice, as 3 of 11 untreated animals died prior to completion of the 3-week experimental period, whereas none of the 9 clenbuterol-treated animals died. Clenbuterol treatment significantly increased the relative mass (P<0.001) and relative tetanic force production (P<0.01) of the soleus of dystrophic animals, most likely due to increases in protein accretion and improved regeneration. The plantaris of clenbuterol-treated dystrophic animals also exhibited higher mass (P<0.05) and higher absolute forces than untreated mice. The results from this study show that clenbuterol could be a valuable adjunct to treatments of muscle wasting diseases such as muscular dystrophy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0022-510X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
7
|
pubmed:volume |
157
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
122-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9619633-Administration, Oral,
pubmed-meshheading:9619633-Animals,
pubmed-meshheading:9619633-Clenbuterol,
pubmed-meshheading:9619633-Disease Models, Animal,
pubmed-meshheading:9619633-Heart,
pubmed-meshheading:9619633-Male,
pubmed-meshheading:9619633-Mice,
pubmed-meshheading:9619633-Mice, Mutant Strains,
pubmed-meshheading:9619633-Muscle, Skeletal,
pubmed-meshheading:9619633-Muscle Contraction,
pubmed-meshheading:9619633-Muscle Fatigue,
pubmed-meshheading:9619633-Muscular Dystrophy, Animal,
pubmed-meshheading:9619633-Organ Size
|
pubmed:year |
1998
|
pubmed:articleTitle |
Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol.
|
pubmed:affiliation |
Department of Physiology, The University of Melbourne, Parkville, Victoria, Australia. AlanHayes@vut.edu.au
|
pubmed:publicationType |
Journal Article,
Comparative Study
|